UNSPSC 51111611: Teniposide

This classification denotes an epipodophyllotoxin compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 957E6438QA. European Medicines Agency schedules Teniposide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10895MIG. Teniposide generally arises in the molecular formula C32H32O13S.

UNSPSC 51111611 Teniposide, a Commodity code, reflects state pharmaceutical procurement focused on sourcing this topoisomerase II inhibitor chemotherapy agent through alternative supply-chain models that bypass traditional pharmacy benefit managers and wholesalers. The Texas Health and Human Services Commission's recent RFI (HHS0017013, posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription fulfillment under its Therapeutic Pharmacy Initiative, targeting improved cost management and supply efficiency for state employee and Medicaid beneficiary populations. State agencies buying under this code are evaluating direct contracting arrangements with pharmaceutical manufacturers based on negotiated net pricing without traditional rebate structures, alongside outcomes-based or value-based payment models. The procurement model emphasizes vendor experience with self-insured employer and government health-plan contracting, dedicated pharmacy partnerships, and participation in purchasing consortia spanning multiple government jurisdictions.

The Texas HHS Commission's RFI marks the only recent documented state-local opportunity under this code. As a preliminary market-intelligence vehicle rather than a binding solicitation, it does not carry award value or formal evaluation timelines but signals the state's intent to develop formal RFP-based procurement for direct-to-manufacturer teniposide supply once vendor capability and market conditions are assessed. The absence of additional recent opportunities under the code suggests limited current activity in state and local teniposide procurement at the direct-to-manufacturer level, though the Texas initiative may establish a model for replication across other state Medicaid and employee health programs.